Nymox re-files urine test kit for Alzheimer's with FDA
This article was originally published in Clinica
Executive Summary
In another attempt to gain US market approval for a test kit version of its urine test for Alzheimer's disease, Nymox Pharmaceutical has filed with the FDA an amendment to its previously rejected premarket approval (PMA) application for the product.